Ionis Pharmaceuticals Crecimiento futuro

Future controles de criterios 1/6

Ionis Pharmaceuticals se prevé un crecimiento anual de los beneficios y los ingresos de 30.3% y 17.8% respectivamente. Se prevé que el BPA sea de grow en 30.4% al año. Se prevé que la rentabilidad de los fondos propios sea de -326.8% en 3 años.

Información clave

32.4%

Tasa de crecimiento de los beneficios

32.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	19.4%
Tasa de crecimiento de los ingresos	18.4%
Rentabilidad financiera futura	-185.8%
Cobertura de analistas	Good
Última actualización	19 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

LSE:0JDI - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	1,105	-281	-244	-117	14
12/31/2025	766	-504	-467	-323	21
12/31/2024	624	-572	-499	-406	22
12/31/2023	788	-366	-336	-308	N/A
9/30/2023	615	-409	-574	-541	N/A
6/30/2023	631	-309	-493	-456	N/A
3/31/2023	576	-329	-405	-377	N/A
12/31/2022	587	-270	-294	-274	N/A
9/30/2022	875	7	110	130	N/A
6/30/2022	849	-28	82	98	N/A
3/31/2022	841	-4	35	54	N/A
12/31/2021	810	-29	13	31	N/A
9/30/2021	661	-608	-96	-75	N/A
6/30/2021	688	-550	-59	-30	N/A
3/31/2021	708	-495	-45	-11	N/A
12/31/2020	729	-444	-5	36	N/A
9/30/2020	933	94	173	216	N/A
6/30/2020	940	145	165	213	N/A
3/31/2020	959	169	188	230	N/A
12/31/2019	1,123	281	309	346	N/A
9/30/2019	821	433	154	183	N/A
6/30/2019	799	402	154	170	N/A
3/31/2019	752	366	679	697	N/A
12/31/2018	600	277	585	603	N/A
9/30/2018	575	-41	485	508	N/A
6/30/2018	548	-38	525	563	N/A
3/31/2018	543	9	28	65	N/A
12/31/2017	514	19	136	174	N/A
9/30/2017	507	42	N/A	127	N/A
6/30/2017	499	52	N/A	122	N/A
3/31/2017	426	-15	N/A	86	N/A
12/31/2016	373	-60	N/A	-112	N/A
9/30/2016	238	-184	N/A	-123	N/A
6/30/2016	176	-227	N/A	-111	N/A
3/31/2016	258	-134	N/A	-12	N/A
12/31/2015	284	-88	N/A	21	N/A
9/30/2015	317	14	N/A	129	N/A
6/30/2015	312	23	N/A	95	N/A
3/31/2015	249	-24	N/A	-4	N/A
12/31/2014	214	-39	N/A	6	N/A
9/30/2014	172	-94	N/A	-79	N/A
6/30/2014	151	-92	N/A	-15	N/A
3/31/2014	132	-90	N/A	42	N/A
12/31/2013	147	-61	N/A	63	N/A
9/30/2013	125	-39	N/A	114	N/A
6/30/2013	113	-52	N/A	23	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: 0JDI se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: 0JDI se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: 0JDI se prevé que siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: 0JDISe prevé que los ingresos de la empresa (19.8% al año) crezcan más deprisa que los del mercado UK (4% al año).

Ingresos de alto crecimiento: 0JDISe prevé que los ingresos de la empresa (18% al año) crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: 0JDI se prevé que no sea rentable en 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Ionis Pharmaceuticals Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2023

Ionis Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2022

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Recent updates

Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome

Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224

Ionis Pharmaceuticals, Inc. Announces Executive Changes

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: US$2.56 loss per share (vs US$1.90 loss in FY 2022)

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Grants Orphan Drug Designation to the Investigational Medicine Olezarsen for the Treatment of FCS

Founder recently sold US$1.2m worth of stock

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 Oasis-Hae Study of Investigational Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Ionis and AstraZeneca's WAINUA

Ionis Pharmaceuticals, Inc. Appoints Michael Yang as a Member of Board

Ionis Pharmaceuticals, Inc. Shares Positive Clinical Update from Ongoing Trial of Ion582 for Angelman Syndrome

Ionis Presents Positive Two-Year Results from the Phase 2 Open-Label Extension Study of Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: US$1.03 loss per share (vs US$0.33 loss in 3Q 2022)

Ionis Pharmaceuticals, Inc. Announces Positive Olezarsen Topline Results from Phase 3 Study in People with Facilitate Chylomicronemia Syndrome

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$0.74 loss in 2Q 2022)

Ionis Completes Enrollment in Phase 3 Cardio-TTRansform Study in Patients with TTR-Mediated Amyloid Cardiomyopathy

Ionis Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Ionis Pharmaceuticals, Inc. Announces Positive Topline, 85-Week Data from the Phase 3 Neuro-Ttransform Study in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Ionis Pharmaceuticals, Inc. Announces New Data Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Medical Needs After Gene Therapy

Ionis Pharmaceuticals, Inc. Announces Positive Donidalorsen Late-Stage Clinical Progress in HAE

First quarter 2023 earnings released: US$0.87 loss per share (vs US$0.46 loss in 1Q 2022)

Full year 2022 earnings released: US$1.90 loss per share (vs US$0.20 loss in FY 2021)

Founder recently sold US$1.0m worth of stock

Ionis Pharmaceuticals, Inc. Announces GSK Has Advanced Bepirovirsen into Phase 3 Development

Ionis Receives FDA Fast Track Designation for Olezarsen in Patients with Familial Chylomicronemia Syndrome

Ionis Pharmaceuticals, Inc. Announces European Medicines Agency Accepts Marketing Authorization Application of Tofersen to Treat Rare, Genetic Form of ALS

Insufficient new directors

Third quarter 2022 earnings released: US$0.33 loss per share (vs US$0.58 loss in 3Q 2021)

Ionis Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2022

Ionis Pharmaceuticals, Inc. Announces Positive Data from GSK's Phase 2b Clinical Study of Bepirovirsen

Ionis Pharmaceuticals, Inc. Presents Positive Phase 2 Data in Patients with IgA Nephropathy At American Society of Nephrology's Kidney Week 2022

Ionis Pharmaceuticals, Inc. Announces Positive Results from Fesomersen Development Program

Oxford Properties Group, Inc. acquired 18.4-Acre Life Science Campus and Corporate Headquarters of Ionis Pharmaceutical in San Diego from Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS).

Ionis Pharmaceuticals, Inc. Provides Update on Development Program Evaluating PCSK9 Antisense Medicine for the Treatment of Hypercholesterolemia

Ionis Pharmaceuticals, Inc. Presents Positive Results from Phase 3 Neuro-Ttransform Study At International Symposium on Amyloidosis

Second quarter 2022 earnings released: US$0.74 loss per share (vs US$0.57 loss in 2Q 2021)

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 2B Clinical Study of Fesomersen

Ionis Pharmaceuticals, Inc. Announces FDA Accepts New Drug Application and Grants Priority Review of Tofersen for A Rare, Genetic Form of ALS

Ionis Announces Enrollment Completion of Phase 3 Lp(a) HORIZON Cardiovascular Outcomes Study of Pelacarsen

Frederick Muto Retires from Ionis Pharmaceuticals, Inc., Effective July 15, 2022

Ionis Partner Licenses Rare Kidney Disease Treatment and Will Advance into Phase 3 Clinical Study

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Presentation of Positive Phase 2B Data for Chronic Hepatitis B Treatment At the EASL International Liver Congress™

Ionis Announces Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the Phase 3 Neuro-Ttransform Study for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (Attrv-Pn)

Ionis Pharmaceuticals, Inc. Announces Results from the Phase 3 Valor Study and Its Open-Label Extension of tofersen

First quarter 2022 earnings released: US$0.46 loss per share (vs US$0.64 loss in 1Q 2021)

Ionis Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2022

Ionis and Astrazeneca Announce Positive Data for Etesian Phase 2B Study of Antisense Medicine Targeting PCSK9 at 2022 American College of Cardiology Scientific Session

Biogen Inc. and Ionis Pharmaceuticals, Inc. Announce Topline Phase 1 Study Results of BIIB078 in C9orf72 Amyotrophic Lateral Sclerosis

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Ionis Pharmaceuticals, Inc. Announce Discontinuation of Vupanorsen Clinical Development Program

Ionis Pharmaceuticals, Inc. Announces eplontersen Receives Orphan Drug Designation from U.S. FDA

Independent Director Peter Reikes has left the company

Ionis Announces That Pfizer Reports Topline Results from Phase 2B Clinical Study of Vupanorsen

Third quarter 2021 earnings released: US$0.58 loss per share (vs US$0.22 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.57 loss per share (vs US$0.23 loss in 2Q 2020)

Ionis Pharmaceuticals, Inc. Continues to Advance in the Clinic as the Potential First-In-Class Treatment for Lipoprotein(a) or Lp(a)-Driven Cardiovascular Disease

High number of new directors

Independent Director Breaux Castleman has left the company

First quarter 2021 earnings released: US$0.64 loss per share (vs US$0.35 loss in 1Q 2020)

Full year 2020 earnings released: US$3.22 loss per share (vs US$2.12 profit in FY 2019)

Revenue beats expectations

Ionis Pharmaceuticals, Inc. Appoints Eugene Schneider as Executive Vice President and Chief Clinical Development Officer

Stanley T. Crooke to Retire from Ionis Pharmaceuticals, Inc. as Executive Chairman

Ionis Pharmaceuticals, Inc. Announces Initiation of Global Phase 3 BALANCE Study for AKCEA-APOCIII-LRX in Patients with Familial Chylomicronemia Syndrome

Ionis Announces Third Investigational Antisense Medicine to Treat Nonalcoholic Steatohepatitis (NASH) Enters Development